Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment

被引:9
作者
Balogh, Aniko [1 ,2 ]
Milibak, Tibor [2 ]
Szabo, Viktoria [1 ]
Nagy, Zoltan Zsolt [1 ]
Resch, Miklos D. [1 ]
机构
[1] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary
[2] Uzsoki Hosp, Dept Ophthalmol, Budapest, Hungary
来源
PLOS ONE | 2020年 / 15卷 / 06期
关键词
HEPATOCYTE GROWTH-FACTOR; STEM-CELL FACTOR; CHEMOKINES; INDUCTION;
D O I
10.1371/journal.pone.0234525
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Our purpose was to evaluate the concentrations of vitreous cytokines in patients with rhegmatogenous retinal detachment (RRD). We hypothesized that patients with macula on RRD have lower levels of cytokines compared to patients with macula off RRD and proliferative vitreoretinopathy (PVR). Vitreous fluids were collected during 23G pars plana vitrectomy from 58 eyes of 58 patients. Indication for vitrectomy included macula off and macula on RRD, PVR, and idiopathic epiretinal membrane (ERM). A multiplex chemiluminescent immunoassay was performed to measure the concentrations of 48 cytokines, chemokines, and growth factors. Levels of HGF, IL-6, IL-8, IL-16, IFN-gamma, MCP-1, and MIF were significantly higher in all groups of retinal detachment compared to ERM. Levels of CTACK, eotaxin, G-CSF, IP-10, MIG, SCF, SCGF-beta, SDF-1alpha were significantly higher in PVR compared to macula on RRD and ERM. Levels of IL-1ra, IL-5, IL-9, M-CSF, MIP-1alpha, and TRIAL were significantly higher in PVR compared to macula on RRD. Our results indicate that the position of macula lutea and the presence of PVR significantly influence vitreous cytokine expression. The detected proteins may serve as biomarkers to estimate the possibility of PVR formation and may help to invent personalized therapeutic strategies to slow down or prevent PVR.
引用
收藏
页数:15
相关论文
共 36 条
[1]   Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy [J].
Abu El-Asrar, Ahmed M. ;
Struyf, Sofie ;
Kangave, Dustan ;
Geboes, Karel ;
Van Damme, Jo .
EUROPEAN CYTOKINE NETWORK, 2006, 17 (03) :155-165
[2]  
[Anonymous], 2016, THE TOTAL AUDIENCE R
[3]  
[Anonymous], 2018, LANCET ONCOL, V19, pe581
[4]   Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy - Results from a randomized, double-blind, controlled clinical trial [J].
Asaria, RHY ;
Kon, CH ;
Bunce, C ;
Charteris, DG ;
Wong, D ;
Khaw, PT ;
Aylward, GW .
OPHTHALMOLOGY, 2001, 108 (07) :1179-1183
[5]   Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding [J].
Cox, Jennifer H. ;
Dean, Richard A. ;
Roberts, Clive R. ;
Overall, Christopher M. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (28) :19389-19399
[6]  
Duarte RF, 2000, BLOOD, V96, P3422
[7]   Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment [J].
Garweg, Justus G. ;
Zandi, Souska ;
Pfister, Isabel ;
Rieben, Robert ;
Skowronska, Magdalena ;
Tappeiner, Christoph .
ACTA OPHTHALMOLOGICA, 2019, 97 (04) :E580-E588
[8]   Pathophysiology of Proliferative Vitreoretinopathy in Retinal Detachment [J].
Garweg, Justus G. ;
Tappeiner, Christoph ;
Halberstadt, Markus .
SURVEY OF OPHTHALMOLOGY, 2013, 58 (04) :321-329
[9]   Hepatocyte growth factor/scatter factor in the eye [J].
Grierson, I ;
Heathcote, L ;
Hiscott, P ;
Hogg, P ;
Briggs, M ;
Hagan, S .
PROGRESS IN RETINAL AND EYE RESEARCH, 2000, 19 (06) :779-802
[10]   THE CLASSIFICATION OF RETINAL-DETACHMENT WITH PROLIFERATIVE VITREORETINOPATHY [J].
HILTON, G .
OPHTHALMOLOGY, 1983, 90 (02) :121-125